Eris Lifesciences Limited — Board Meeting, 19-05-2025: Outcome of Board Meeting

Eris Lifesciences has announced a board meeting on May 19, 2025, approving the consolidated financial results for the quarter and year ended March 31, 2025. Revenue jumped to Rs 2,893.64 Cr from Rs 2,009.15 Cr, while net profit dipped slightly to Rs 374.67 Cr from Rs 397.12 Cr. The company is progressing with integrating Biocon’s branded formulations and Swiss Parenterals. An interim dividend of Rs 7.35 per share was declared. New key appointments include M/s Ravi Kapoor & Associates as Secretarial Auditor (5-year term) and re-appointment of M/s Kiran J. Mehta & Co. as Cost Auditors for FY26.